Vol. 14. Núm. 11.
Páginas 612-616 (Mayo 2024)

Actualización
Hepatitis autoinmune

Autoimmune hepatitis

M. López GómezM. Hernández CondeE.C. Abad IzquierdoJ.L. Calleja Panero
Doi : https://10.1016/j.med.2024.05.021
Opciones
Resumen

La hepatitis autoinmune es una enfermedad inflamatoria crónica que se caracteriza por elevación de las transaminasas, hipergammaglobulinemia y presencia de autoanticuerpos. El diagnóstico se realiza mediante criterios bioquímicos, serológicos e histológicos. El objetivo del tratamiento es evitar la progresión a cirrosis y sus complicaciones. En el tratamiento se administran corticoides e inmunosupresores.

Palabras clave
Hepatitis autoinmune
Enfermedad hepática crónica
Hipertransaminasemia
Hipergammaglobulinemia
Abstract

Autoimmune hepatitis is a chronic inflammatory disease characterized by elevated transaminases, hypergammaglobulinemia, and the presence of autoantibodies. It is diagnosed through biochemical, serological, and histological criteria. The goal of treatment is to prevent progression to cirrhosis and its complications. It is treated by administering corticosteroids and immunosuppressants.

Keywords
Autoimmune hepatitis
Chronic liver disease
Hypertransaminasemia
Hypergammaglobulinemia

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
EASL
202406051216328668
202406051216328669
Clinical Practice Guidelines: Autoinmune hepatitis. EASL. J Hepatol. 2015 vol.63 971-1004.
[2]
E.L. Krawitt
2024060512163286610
2024060512163286611
.
Autoimmune hepatitis.
N Engl J Med., (2006), 354 pp. 54-66
[3]
A.W. Lohse
2024060512163286612
2024060512163286613
, G. Mieli-Vergani.
Autoimmune hepatitis.
J Hepatol., (2011), 55 pp. 171-182
[4]
K. Zachou
2024060512163286614
2024060512163286615
, P. Muratori, G.K. Koukoulis, A. Granito, N. Gatselis, A. Fabbri, et al.
Review article: autoimmune hepatitis – Current management and chal- lenges.
Aliment Pharmacol Ther., (2013), 38 pp. 887-913
[5]
I. Olivas
2024060512163286616
2024060512163286617
, S. Rodríguez-Tajes, M. Carlota Londoño.
Hepatitis autoinmune: retos y novedades.
Med Clin (Barc)., (2022), 159 pp. 289-298
[6]
C.L. Mack
2024060512163286618
2024060512163286619
, D. Adams, D.N. Assis, N. Kerkar, M.P. Manns, M.J. Mayo, et al.
Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the study of liver diseases.
Hepatology., (2020), 72 pp. 671-722
[7]
B. Terziroli
2024060512163286620
2024060512163286621
Beretta-Piccoli, G. Mieli-Vergani, D. Vergani.
Autoimmune hepatitis: Serum autoantibodies in clinical practice.
Clin Rev Allergy Immunol., (2022), 63 pp. 124-137
[8]
A.J. Czaja
2024060512163286622
2024060512163286623
.
Performance parameters of the conventional serological markers for autoimmune hepatitis.
Dig Dis Sci., (2011), 56 pp. 545-554
[9]
A.J. Czaja
2024060512163286624
2024060512163286625
.
Autoantibody-negative autoimmune hepatitis.
Dig Dis Sci., (2012), 57 pp. 610-624
[10]
M. Sebode
2024060512163286626
2024060512163286627
, C. Weiler-Normann, T. Liwinski, C. Schramm.
Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance.
Front Immunol., (2018), 9 pp. 609
[11]
R.T. Stravitz
2024060512163286628
2024060512163286629
, J.H. Lefkowitch, R.J. Fontana, M.E. Gershwin, P.S. Leung, R.K. Sterling, et al.
Acute Liver Failure Study Group. Autoimmune acute liver failure: proposed clinical and histological criteria.
Hepatology., (2011), 53 pp. 517-526
[12]
E. Björnsson
2024060512163286630
2024060512163286631
, J. Talwalkar, S. Treeprasertsuk, P.S. Kamath, N. Takahashi, S. Sanderson, et al.
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.
Hepatology., (2010), 51 pp. 2040-2048
[13]
European
2024060512163286632
2024060512163286633
Association for the Study of the Liver.
Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair: Panel members; EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury.
J Hepatol., (2019), 70 pp. 1222-1261
[14]
Á. Díaz-González
2024060512163286634
2024060512163286635
, M. Hernández-Guerra, I. Pérez-Medrano, V. Sapena, M. Riveiro-Barciela, A. Barreira-Díaz, et al.
ColHai Registry. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
Hepatology., (2023), 77 pp. 1095-1105
[15]
C. Ferre-Aracil
2024060512163286636
2024060512163286637
, M. Riveiro-Barciela, M. Trapero-Marugán, M. Rodríguez-Perálvarez, L.P. Llovet, L. Téllez, et al.
Tacrolimus as an effective and durable second-line treatment for chronic autoimmune hepatitis: A multicentric study.
Dig Dis Sci., (2021), 66 pp. 2826-2832
[16]
Y.Y. Chung
2024060512163286638
2024060512163286639
, M.A. Heneghan.
Autoimmune hepatitis in pregnancy: Pearls and pitflls.
Hepatology., (2022), 76 pp. 502-517